Control of cardiac energy turnover by cytoplasmic phosphates: 31P-NMR study.
Energy flux, estimated from the cardiac work index (pressure-rate product) and the rate of oxygen consumption, was varied in different ways; and the free concentrations of cytosolic phosphates were detected by the 31P-nuclear magnetic resonance method. A reversible decrease in phosphocreatine (PCr) and concomitant increase in [ADP] at nearly constant Pi were induced by 2-deoxyglucose (2-DG) treatment and its subsequent washout and were followed by a reversible suppression of pressure-rate product and elevation of end-diastolic pressure. 2-DG treatment also resulted in an irreversible and severe reduction of the cytosolic adenine nucleotide pool (to approximately one-third of control value) that did not recover during 2-DG washout. Reduction of the energy turnover rate, either by suppression of the PCr shuttle with iodoacetamide or by inhibition of the respiratory chain with amytal, was associated with a drop of PCr level, an elevation of both [ADP] and [Pi], and a rise of end-diastolic pressure. In contrast, a decrease in energy flux by reduction of perfusate Ca2+ led to a PCr rise and a fall in [ADP] and [Pi]. Most of these experimental groups were exposed to two types of loads, isoproterenol stimulation and coronary flow (CF) elevation. Iodoacetamide-treated hearts showed a poor mechanical response to both types of loads compared with other groups. The metabolic response to isoproterenol was uniform in all groups and was associated with some decrease in PCr and increase of [ADP] and [Pi], implying limitations in the respiratory chain.(ABSTRACT TRUNCATED AT 250 WORDS)
Institute of Experimental Cardiology, USSR Cardiology Research Center, Moscow.
V V
VV
Kupriyanov
V L
VL
Lakomkin
O V
OV
Korchazhkina
Steinschneider AYa
V I
VI
Kapelko
V A
VA
Saks
D000227:Adenine Nucleotides / Q000378:metabolism; D000654:Amobarbital / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000494:pharmacology; D003326:Coronary Circulation / Q000502:physiology; D003402:Creatine Kinase / Q000037:antagonists & inhibitors; D003593:Cytoplasm / Q000378:metabolism*; D004734:Energy Metabolism; D066298:In Vitro Techniques; D007460:Iodoacetamide / Q000494:pharmacology; D007545:Isoproterenol / Q000494:pharmacology; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D009200:Myocardial Contraction; D009206:Myocardium / Q000378:metabolism*; D010101:Oxygen Consumption / Q000187:drug effects; D010710:Phosphates / Q000502:physiology*; D010758:Phosphorus; D051381:Rats; D011919:Rats, Inbred Strains
D000227:Adenine Nucleotides; D010710:Phosphates; D010758:Phosphorus; D003402:Creatine Kinase; D000654:Amobarbital; D007545:Isoproterenol; D002118:Calcium; D007460:Iodoacetamide